Update
NNMT inhibitors and the NAD+ story: a chain of plausible links
5-Amino-1MQ is sold on a mechanism with support at every step and no human trial at any step. That combination is worth understanding on its own terms.
The argument for 5-Amino-1MQ runs like this. NNMT consumes nicotinamide, the methyl-donor route into NAD+ synthesis. NAD+ is central to the metabolism that burns fat. Inhibiting NNMT should therefore free up NAD+ precursors and increase fat oxidation, particularly in visceral fat where NNMT expression is high.
Every link in that chain has support in cell and rodent work, and the mouse data is genuinely striking: reduced fat mass in obese animals with no change in food intake. This is not a mechanism invented for marketing.
It is also not a mechanism that has been tested in a person. There is no completed human trial of 5-Amino-1MQ of any kind: no efficacy trial, and no pharmacokinetic study establishing what an oral dose achieves in human blood. The doses in circulation are rodent doses converted by body weight. That is not how human dosing is established and is not a conservative method.
A chain of plausible links is exactly the kind of argument that turns out to be wrong in ways nobody anticipated, because each step holds and the conclusion still fails. The history of metabolic drug development is largely a history of that. It is not a reason to dismiss the compound; it is a reason not to treat the mechanism as a finding.
The practical version of this problem: 5-Amino-1MQ is most often taken alongside a GLP-1, which produces a large and well-documented weight reduction on its own. Whatever happens, the incretin agonist explains it, and the person running both learns nothing about the compound they were curious about.
Compounds this concerns
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.